NASDAQ
No price data available for this timeframe.
Recursion Pharmaceuticals, Inc. (RXRX) has had 7 insider transactions recently, with net insider activity of -$193K (net selling). The most active insider is Khan Najat (Director, officer: ceo and president).
Total Transactions
7
2 buys /5 sells
Shares Acquired
8,856
Transactions: 2•Avg: 4,428
Shares Disposed
202,173
Transactions: 5•Avg: 40,434.6
Net Activity
-193,317
Net Selling•Ratio: 40%
Q3 2026(Current) | 8,856 | 202,173 | -193,317 | 40.00% |
Q2 2026 | 847,138 | 752,558 | +94,580 | 60.87% |
Q1 2026 | 2,977,041 | 1,255,644 | +1,721,397 | 53.57% |
Q4 2025 | 679,678 | 1,284,996 | -605,318 | 43.48% |
Q3 2025 | 866,414 | 1,709,459 | -843,045 | 44.44% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q3 2026
Acquired vs Disposed Shares
Net Distribution: 193,317 shares•Acquired/Disposed Ratio: 40%
Net Activity | |||||
|---|---|---|---|---|---|
KN Khan Najat | Director, officer: ceo and president | 9 | 1,703,892 | 344,132 | +1,359,760 |
BB Borgeson Blake | Director | 9 | 88,424 | 770,000 | -681,576 |
GC Gibson Christopher | Director | 43 | 530,346 | 1,120,450 | -590,104 |
HD Hallett David | Officer: chief scientific officer | 12 | 526,318 | 1,038,233 | -511,915 |
TBR Taylor Ben R | Officer: chief financial officer | 13 | 470,533 | 183,665 | +286,868 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2026-08-17 | Director, officer: ceo and president | Sale | 80,498 | $3.16 | $254,373.68 | 2,095,298 | |
2026-08-17 | Officer: chief scientific officer | Sale | 26,657 | $3.16 | $84,236.12 | 1,043,837 | |
2026-08-17 | Officer: chief financial officer | Sale | 25,018 | $3.16 | $79,056.88 | 1,076,858 | |
2026-08-04 | Director | Sale | 30,000 | $3.25 | $97,500 | 6,188,287 | |
2026-07-07 | Director | Sale | 40,000 | $3.96 | $158,500 | 6,218,287 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
KN Khan Najat | Director, officer: ceo and president | Aug 18, 2026 | |
HD Hallett David | Officer: chief scientific officer | Aug 18, 2026 | |
TBR Taylor Ben R | Officer: chief financial officer | Aug 18, 2026 | |
BB Borgeson Blake | Director | Aug 6, 2026 | |
BB Borgeson Blake | Director | Jul 9, 2026 |
Net change in shares shown on right